Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Divi's LaboratoriesNSE:DIVISLAB +0.32%89 Cash-to-Debt is 462.29 as of Mar. 2026, which is 3% above its 10-year median of 446.98. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 89/100 and a GF Value™ of ₹6,937.49 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 950 Drug Manufacturers companies, Divi's Laboratories ranks better than 92.21% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Divi's Laboratories's cash to debt ratio for the quarter that ended in Mar. 2026 was 462.29.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Divi's Laboratoriescould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Divi's Laboratories's Cash-to-Debt or its related term are showing as below:
NSE:DIVISLAB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 13.37 Med: 446.98 Max: 1233.67
Current: 462.29
During the past 13 years, Divi's Laboratories's highest Cash to Debt Ratio was 1233.67. The lowest was 13.37. And the median was 446.98.
NSE:DIVISLAB's Cash-to-Debt is ranked better than 92.21% of 950
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs NSE:DIVISLAB: 462.29
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Divi's Laboratories Cash-to-Debt Related Terms
Divi's Laboratories Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Divi's Laboratories's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Divi's Laboratories Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Divi's Laboratories's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Divi's Laboratories (NSE:DIVISLAB) has a Cash-to-Debt of 462.29 as of Mar. 2026. This is near median its historical median of 446.98. Over the past decade, Divi's Laboratories' Cash-to-Debt has ranged from 13.37 to 1,233.67. According to the industry distribution chart, Divi's Laboratories ranks #74 out of 950 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is Divi's Laboratories' Cash-to-Debt too high?
Divi's Laboratories' current Cash-to-Debt of 462.29 is near median its 10-year median of 446.98. Over the past 10 years, this metric has ranged from a low of 13.37 to a high of 1,233.67. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Divi's Laboratories' value of 462.29 is 47072.4% above this industry median. Based on the distribution chart, Divi's Laboratories ranks #74 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Divi's Laboratories has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Divi's Laboratories ranks #74 out of 950 companies for Cash-to-Debt. This places Divi's Laboratories in the top 8% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. Divi's Laboratories' value of 462.29 is 47072.4% above this benchmark. Historically, Divi's Laboratories' own Cash-to-Debt has ranged from 13.37 to 1,233.67 over the past decade. While the company's 10-year median is 446.98 vs. the industry median of 0.98, Divi's Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Divi's Laboratories's current Cash-to-Debt of 462.29 is 47072.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Divi's Laboratories's current Cash-to-Debt is 462.29, which is near median its own 10-year median of 446.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,937.49, compared to a current price of ₹8,597.00 — trading 23.9% above its estimated fair value. The current Cash-to-Debt is 462.29, which is near median its 10-year median of 446.98 and 47072.4% above the Drug Manufacturers industry median of 0.98. Divi's Laboratories' overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Cash-to-Debt is 462.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued.
The current stock price of ₹8,597.00 is trading 23.9% above its estimated GF Value™ of ₹6,937.49.
GuruFocus considers Divi's Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:DIVISLAB:
Cash-to-Debt: 462.29 (near median its 10-year median of 446.98)
GF Value™: ₹6,937.49 vs. price of ₹8,597.00 (23.9% above fair value)
Industry Position: 47072.4% above the Drug Manufacturers median (#74 of 950)
No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
89GF Score
Get the complete analysis for NSE:DIVISLAB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DIVISLAB has been successfully added to your 
